NCT03192397View on ClinicalTrials.gov

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 9, 2017

Primary Completion Date

August 21, 2023

Study Completion Date

May 21, 2027

Conditions
Acute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionChronic Myelogenous Leukemia, BCR-ABL1 Positive in RemissionChronic Myelomonocytic Leukemia in RemissionGraft Versus Host DiseaseHodgkin LymphomaMinimal Residual DiseaseMyelodysplastic SyndromeMyeloproliferative NeoplasmNon-Hodgkin LymphomaPlasma Cell MyelomaSevere Aplastic AnemiaWaldenstrom Macroglobulinemia
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic hematopoietic stem cell transplant

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Melphalan Hydrochloride

Given IV

DRUG

Mycophenolate Mofetil

Given IV

DRUG

Sirolimus

Given IV and PO

RADIATION

Total-Body Irradiation

Undergo TBI

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT03192397 - Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | Biotech Hunter | Biotech Hunter